Yumanity Therapeutics, Inc. (YMTX)

NASDAQ: YMTX · IEX Real-Time Price · USD
1.66
-0.01 (-0.60%)
At close: Aug 18, 2022 4:00 PM
1.72
+0.06 (3.61%)
After-hours: Aug 18, 2022 5:16 PM EDT
-0.60%
Market Cap 18.02M
Revenue (ttm) 5.08M
Net Income (ttm) -38.59M
Shares Out 10.86M
EPS (ttm) -4.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,381
Open 1.71
Previous Close 1.67
Day's Range 1.66 - 1.71
52-Week Range 0.95 - 13.90
Beta n/a
Analysts Buy
Price Target 35.70 (+2,050.6%)
Earnings Date Aug 10, 2022

About YMTX

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Pa... [Read more...]

Industry Biotechnology
IPO Date Feb 11, 2016
CEO Meenu Chhabra
Employees 40
Stock Exchange NASDAQ
Ticker Symbol YMTX
Full Company Profile

Financial Performance

In 2021, YMTX's revenue was $8.04 million, an increase of 16.65% compared to the previous year's $6.90 million. Losses were -$39.50 million, -31.28% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for YMTX stock is "Buy." The 12-month stock price forecast is 35.7, which is an increase of 2,050.60% from the latest price.

Price Target
$35.7
(2,050.60% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of...

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Yumanity Therapeutics, Inc. (NasdaqCM: ...

Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?

Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after announcing two definitive agreements. including a merger.

Yumanity Therapeutics Shares Trading Higher Today - Read Here Why

Yumanity Therapeutics Inc (NASDAQ: YMTX) has agreed to sell its lead clinical-stage product candidate, YTX-7739, and discovery-stage neuroscience candidates to Janssen Pharmaceutica NV, a unit of Johnso...

Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a ...

Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates

Yumanity (YMTX) delivered earnings and revenue surprises of -21.57% and 31.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therap...

Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring

BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

Yumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's Disease

The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's (NASDAQ: YMTX) multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease.  The FDA has not halted...

Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

Yumanity's Approach to Neurodegenerative Diseases Validated by Two External Collaborations

Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment

Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying thera...

Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Announced Successful Phase 1b trial for YTX-7739 in Parkinson's disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles

Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data

Yumanity Therapeutics Inc (NASDAQ: YMTX) reported topline data from Phase 1b trial of its lead product candidate, YTX-7739, for mild-to-moderate Parkinson's disease. The study achieved its primary endpo...

Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Pa...

YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson's disease

Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

YTX-7739 shown to inhibit its novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson's disease

Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson's disease

Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therap...

Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience Conference

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying ther...

Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a ...

YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of Parkinson's disease YTX-7739 is Yumanity's lead product candidate in clinical development for the treatment of ...

Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice Preside...

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative d...